Printer Friendly

CEL-SCI NAMES DR. EVAN M. HERSH TO ITS SCIENTIFIC ADVISORY BOARD

 CEL-SCI NAMES DR. EVAN M. HERSH
 TO ITS SCIENTIFIC ADVISORY BOARD
 ALEXANDRIA, Va., July 8 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ: CELI) today announces the addition of Dr. Evan M. Hersh to the company's Scientific Advisory Board.
 Hersh is vice-head, Department of Internal Medicine; chief, section of Hematology/Oncology, Department of Internal Medicine, University of Arizona College of Medicine, Tucson, Ariz.; and the director of clinical research at the Arizona Cancer Center, Tucson. For the five years prior to Hersh's appointment in Arizona, he was chairman of the Department of Clinical Immunology at the M.D. Anderson Cancer Center of the University of Texas in Houston and chief, Section of Immunology, Department of Laboratory Medicine. Prior to that he was chief of the Section of Immunology in the Department of Medicine at the M.D. Anderson Cancer Center.
 Among many other committees, Hersh is a member of the AIDS Vaccine Data Monitoring and Safety Board, NIAID, a member of the Scientific Advisory Board, Coordinating Council for Cancer Research and the board of directors of the Berlex Foundation.
 Hersh's group at M.D. Anderson was the first to develop Interferon therapy of human cancer and he has been very active in the development of cytokine therapy.
 Maximilian de Clara, president of CEL-SCI Corporation, said: "Dr. Hersh's expertise in immunology with particular focus on cancer and AIDS, CEL-SCI's corporate focus, will be invaluable. We are very excited to see Dr. Hersh's participation."
 CEL-SCI Corporation is the pioneer of combination therapy using lymphokine and cytokine mixtures ("cocktails") for the treatment of cancers and immunodeficiencies. Its 50 percent owned subsidiary, Viral Technologies, Inc., is developing the HGP-30 AIDS vaccine/treatment based on a piece of the core protein.
 -0- 7/8/92
 /CONTACT: Matt Haines of Strategic Growth International, 212-826-9622, or Daryll Strahl, 303-979-5735, both for CEL-SCI/
 (CELI) CO: CEL-SCI Corporation ST: Virginia IN: MTC SU: PER


DC -- DC002 -- 7296 07/08/92 09:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 8, 1992
Words:320
Previous Article:NOVA PHARMACEUTICAL SIGNS $4.3 MILLION CONTRACT WITH THE NATIONAL INSTITUTE OF MENTAL HEALTH
Next Article:DIGITAL ANNOUNCES PC PRICE CUTS OF 35-TO-42 PERCENT, INTRODUCES NEW PC
Topics:


Related Articles
CEL-SCI CORPORATION ANNOUNCES ADDITION OF NEW MEMBER TO ITS SCIENTIFIC ADVISORY BOARD
CEL-SCI ENTERS PROCESS DEVELOPMENT AGREEMENT WITH ROGER WILLIAMS MEDICAL CENTER
CEL-SCI CORPORATION ANNOUNCES THE ADDITION OF A NEW MEMBER TO ITS SCIENTIFIC ADVISORY BOARD
CEL-SCI CORPORATION TO LICENSE POTENTIAL DRUG TREATMENT FOR MULTIPLE SCLEROSIS
CEL-SCI Corporation and AIDS ReSEARCH Alliance Announce Results of HGP-30 AIDS Vaccine Study, Plan Further Study
Cel-Sci Acquisition Inc. Announces $ 7.75 Per Share All Cash Offer To Acquire Cel-Sci Corporation.
Cel-Sci Acquisition Inc. Reiterates $7.75 Per Share All Cash Offer To Acquire Cel-Sci Corporation.
Cel-Sci Corporation Hires New Senior Director of Laboratory and Manufacturing Operations.
CEL-SCI Corporation Announces Change in its Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters